
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is a promising company with a strong focus on developing innovative treatments for CNS tumors. Their lead drugs, NEO212 and NEO100, have shown promising results in clinical trials and have the potential to revolutionize drug delivery to the brain. The company's versatile platform and upcoming data sets make it a strong investment opportunity.
Bears say
NeOnc Technologies Hldgs is developing novel molecular technologies for the targeted delivery of therapeutics into the central nervous system, and has shown early signs of success in clinical data for its lead product candidates, NEO100 and NEO212, in the treatment of glioblastoma. While the company has generated interesting data supporting their drug delivery method, they are a small company with a lot on their plate and face competition from other approaches to CNS delivery. With the market for CNS treatments being highly competitive and NeOnc's limited financial resources, the success of their products hinges on their ability to differentiate themselves through efficacy and safety.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares